Success Metrics

Clinical Success Rate
90.0%

Based on 9 completed trials

Completion Rate
90%(9/10)
Active Trials
1(9%)
Results Posted
56%(5 trials)
Terminated
1(9%)

Phase Distribution

Ph phase_2
5
45%
Ph phase_3
1
9%
Ph not_applicable
2
18%
Ph phase_1
3
27%

Phase Distribution

3

Early Stage

5

Mid Stage

1

Late Stage

Phase Distribution11 total trials
Phase 1Safety & dosage
3(27.3%)
Phase 2Efficacy & side effects
5(45.5%)
Phase 3Large-scale testing
1(9.1%)
N/ANon-phased studies
2(18.2%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

90.0%

9 of 10 finished

Non-Completion Rate

10.0%

1 ended early

Currently Active

1

trials recruiting

Total Trials

11

all time

Status Distribution
Active(1)
Completed(9)
Terminated(1)

Detailed Status

Completed9
Terminated1
Active, not recruiting1

Development Timeline

Analytics

Development Status

Total Trials
11
Active
1
Success Rate
90.0%
Most Advanced
Phase 3

Trials by Phase

Phase 13 (27.3%)
Phase 25 (45.5%)
Phase 31 (9.1%)
N/A2 (18.2%)

Trials by Status

terminated19%
active_not_recruiting19%
completed982%

Recent Activity

1 active trials
Showing 5 of 11
active_not_recruitingphase_1

Treatment of Orthostatic Intolerance

NCT00262470
completednot_applicable

Nicotinic Modulation of the Default Network

NCT01223404
completedphase_2

Treatment With Mecamylamine in Smoking and Non-smoking Alcohol Dependent Patients

NCT00342563
completednot_applicable

Study of the Effects of Mecamylamine and Varenicline in Schizophrenia

NCT00455650
completedphase_1

Placebo-Controlled Pilot Trial of Mecamylamine for Treatment of Autism Spectrum Disorders

NCT00773812
View all 11 trials

Clinical Trials (11)

Showing 11 of 11 trials
NCT00262470Phase 1

Treatment of Orthostatic Intolerance

Active Not Recruiting
NCT01223404Not Applicable

Nicotinic Modulation of the Default Network

Completed
NCT00342563Phase 2

Treatment With Mecamylamine in Smoking and Non-smoking Alcohol Dependent Patients

Completed
NCT00455650Not Applicable

Study of the Effects of Mecamylamine and Varenicline in Schizophrenia

Completed
NCT00773812Phase 1

Placebo-Controlled Pilot Trial of Mecamylamine for Treatment of Autism Spectrum Disorders

Completed
NCT00563797Phase 3

Mecamylamine for the Treatment of Patients With Depression and Alcohol Dependence

Completed
NCT00414206Phase 2

Safety and Efficacy of ATG003 in Patients With Wet Age-Related Macular Degeneration (AMD)

Terminated
NCT00018187Phase 1

Combinations of Pharmacologic Smoking Cessation Treatments

Completed
NCT00018161Phase 2

Treatment to Quit Smoking

Completed
NCT00536692Phase 2

Topical Ocular Mecamylamine in Diabetic Macular Edema (DME)

Completed
NCT00593879Phase 2

Flexible Dose Titration Add-on Study to Treat Major Depressive Disorder

Completed

All 11 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
11